LG’s ‘Gemiglo’ wins KFDA approval

The Korea Food and Drug Administration said Wednesday that it has approved the manufacture and distribution of LG Life Sciences’ diabetes treatment, Gemiglo.

Gemiglo, the main substance of which is gemigliptin, is the 19th new drug developed by a domestic pharmaceutical company and fifth new diabetes treatment in the world.

According to the developer, Gemiglo is effective on type-2 diabetes patients, who have a high blood sugar level though their insulin secretion is working. By its use patients have maintained lowered blood sugar levels for up to 52 consecutive weeks, the company said. Those with liver and kidney disorders can also use the medication safely, the company said.

LG said the patients will need to take the 50-milligram pill once a day without fear of side effects including weight gain or lowered blood sugar level.